Generation Bio Co. (NASDAQ:GBIO) major shareholder Venture Associates X. L. Atlas sold 28,862 shares of the stock in a transaction on Friday, September 24th. The stock was sold at an average price of $25.84, for a total transaction of $745,794.08. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of Generation Bio stock traded down $0.99 during trading hours on Friday, reaching $25.41. The company’s stock had a trading volume of 218,560 shares, compared to its average volume of 472,128. The company has a market capitalization of $1.44 billion, a P/E ratio of -12.71 and a beta of 5.56. The stock’s fifty day simple moving average is $23.84 and its two-hundred day simple moving average is $27.66. Generation Bio Co. has a one year low of $19.16 and a one year high of $55.72.
Generation Bio (NASDAQ:GBIO) last posted its earnings results on Tuesday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.08). As a group, equities analysts forecast that Generation Bio Co. will post -2.13 earnings per share for the current year.
A number of equities analysts have recently issued reports on the stock. JMP Securities initiated coverage on shares of Generation Bio in a research report on Tuesday, June 8th. They set an “outperform” rating and a $40.00 price objective on the stock. Zacks Investment Research lowered Generation Bio from a “hold” rating to a “sell” rating in a report on Monday, August 16th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, Generation Bio currently has a consensus rating of “Buy” and an average target price of $43.50.
Generation Bio Company Profile
Generation Bio Co, a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology.
Featured Story: What is a stock portfolio tracker?
Receive News & Ratings for Generation Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Generation Bio and related companies with MarketBeat.com's FREE daily email newsletter.